A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea

NCT04036448 · clinicaltrials.gov ↗

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes
Lymphoma, Mantle-Cell
Lymphoma, Follicular

Interventions

DRUG: REVLIMID®

Sponsor

Celgene